Conflict of interest: Nothing to report.
How common are myeloproliferative neoplasms? A systematic review and meta-analysis
Article first published online: 11 MAR 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 89, Issue 6, pages 581–587, June 2014
How to Cite
Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., O'Rorke, M., Mesa, R., De Vocht, F., Horan, S., Fritschi, L., Clarke, M. and Anderson, L. A. (2014), How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Hematol., 89: 581–587. doi: 10.1002/ajh.23690
- Issue published online: 20 MAY 2014
- Article first published online: 11 MAR 2014
- Accepted manuscript online: 12 FEB 2014 05:58AM EST
- Manuscript Received: 5 FEB 2014
- Manuscript Accepted: 5 FEB 2014
Vol. 90, Issue 9, 850, Article first published online: 30 MAR 2015
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1–99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 0.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. Am. J. Hematol. 89:581–587, 2014. © 2014 Wiley Periodicals, Inc.